{"id":"14c-glpg3970-solution-for-infusion","_chembl":null,"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T06:49:34.340Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123058,"model":"claude-sonnet-4-5-20250929"},"description":"[14C]GLPG3970 solution for infusion is a radiolabeled investigational compound developed by Galapagos NV for Phase 1 clinical studies. The carbon-14 labeling enables tracking of the drug's absorption, distribution, metabolism, and excretion (ADME) in the body to support early-stage drug development.","indications":{"approved":[{"status":"investigational","condition":"ADME study in healthy volunteers","patientPopulation":"Healthy adult volunteers"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"[14C]GLPG3970 solution for infusion","genericName":"[14C]GLPG3970 solution for infusion","companyName":"Galapagos NV","companyId":"galapagos-nv","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}